Research from I. Charreau and co-researchers in the area of HIV/AIDS described.(Report)

"Structured treatment interruptions in chronic HIV infection have been explored as a drug-sparing strategy to reduce drug-related adverse events and costs while maintaining CD4 cell counts at a level high enough to prevent the risk of disease progression. To test the hypothesis and put a figure on the reduction in total medical costs, we conducted a cost study analysis in the setting of a randornized open-label study comparing an intermittent to a continuous antiretroviral regimen," scientists in Creteil, France report (see also HIV/AIDS).

"Four hundred three HIV-1-infected adults who were tolerating highly active antiretroviral therapy (HAART). with a nadir CD4 count …